- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07585058
Safety and Efficacy of Early Non-invasive Brain-Computer Interface-Based Rehabilitation in Acute Ischemic Stroke (SeeBCI)
Safety and Efficacy of Early Non-invasive Brain-Computer Interface-Based Rehabilitation Training in Patients With Acute Ischemic Stroke: The SeeBCI Study
This is a single-center, prospective, randomized, sham-controlled pilot clinical study designed to evaluate the efficacy, safety, and feasibility of early non-invasive electroencephalography-based brain-computer interface (EEG-BCI) rehabilitation training in patients with acute ischemic stroke.
Eligible participants are adults aged 18 to 80 years with acute ischemic stroke, unilateral upper extremity motor impairment on the dominant-hand side, a baseline Fugl-Meyer Assessment of the Upper Extremity (FMA-UE) score of 10 to 50, and confirmed clinical stability 48 to 72 hours after stroke onset.
Participants will be randomly assigned in a 1:1 ratio to receive either real EEG-BCI training plus standard early rehabilitation or sham BCI training plus standard early rehabilitation. Both groups will receive 10 days of training, with two sessions per day and approximately 30 minutes per session.
The primary outcome is the change in FMA-UE score from baseline to 30 days after randomization. Secondary outcomes include changes in FMA-UE, Action Research Arm Test (ARAT), National Institutes of Health Stroke Scale (NIHSS), Modified Barthel Index (MBI), and modified Rankin Scale (mRS). Safety outcomes include symptomatic intracranial hemorrhage, any intracranial hemorrhage, neurological deterioration, seizures, falls, cardiovascular events, and training-related adverse events.
This pilot study aims to provide preliminary evidence regarding the feasibility, safety, and potential efficacy of early EEG-BCI rehabilitation after acute ischemic stroke and to inform the design of future multicenter randomized controlled trials.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Wang Chen, MD
- Número de teléfono: +86 531 68773274
- Correo electrónico: chenwang@sph.com.cn
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Age 18 to 80 years.
- Diagnosis of acute ischemic stroke.
- Stroke onset to randomization within 48 to 72 hours.
- Meets predefined clinical stability criteria before randomization.
- Unilateral upper extremity motor impairment on the dominant-hand side.
- Baseline Fugl-Meyer Assessment of the Upper Extremity (FMA-UE) score between 10 and 50.
- Pre-stroke modified Rankin Scale (mRS) score ≤2.
- Written informed consent obtained from the participant or legally authorized representative.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Doble
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Real EEG-BCI Training + Standard Early Rehabilitation
Participants will receive real electroencephalography-based brain-computer interface (EEG-BCI) training combined with standard early rehabilitation. The EEG-BCI training uses upper extremity motor imagery or motor attempt tasks with real-time decoding of motor intention and virtual hand feedback. Training will be performed twice daily for approximately 30 minutes per session over 10 consecutive days (20 sessions in total). |
Non-invasive EEG-based brain-computer interface training combined with standard early rehabilitation. The intervention includes EEG signal acquisition, motor intention decoding, and real-time virtual hand feedback. Participants perform upper extremity motor imagery or motor attempt tasks. Training is delivered twice daily for approximately 30 minutes per session for 10 consecutive days. Participants in both groups will receive standard early rehabilitation according to clinical practice, including appropriate physical therapy, occupational therapy, task-oriented training, positioning, and other routine rehabilitation interventions. |
|
Comparador falso: Sham BCI Training + Standard Early Rehabilitation
Participants will receive sham BCI training combined with standard early rehabilitation. The sham procedure will match the real EEG-BCI training in appearance, frequency, duration, and workflow, but the feedback will not be generated by real-time EEG-based motor intention decoding. Training will be performed twice daily for approximately 30 minutes per session over 10 consecutive days (20 sessions in total). |
Participants in both groups will receive standard early rehabilitation according to clinical practice, including appropriate physical therapy, occupational therapy, task-oriented training, positioning, and other routine rehabilitation interventions. Sham BCI training designed to maintain participant masking. The procedure matches real EEG-BCI training in device setup, training environment, frequency, duration, and workflow, but the feedback is not linked to the participant's real-time EEG motor intention decoding. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in Fugl-Meyer Assessment of the Upper Extremity (FMA-UE) Score From Baseline to Day 30
Periodo de tiempo: Baseline to Day 30 after randomization
|
The primary outcome is the change in FMA-UE score from baseline (T0) to 30 days after randomization. The FMA-UE evaluates upper extremity motor function after stroke, with scores ranging from 0 to 66. Higher scores indicate better upper extremity motor function. Change score is calculated as the FMA-UE score at Day 30 minus the baseline FMA-UE score. |
Baseline to Day 30 after randomization
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Fugl-Meyer Assessment of the Upper Extremity (FMA-UE) Score
Periodo de tiempo: Baseline, Day 10, Day 30, and Day 90
|
Upper extremity motor function will be assessed using the FMA-UE. The total score ranges from 0 to 66, with higher scores indicating better motor function. |
Baseline, Day 10, Day 30, and Day 90
|
|
Action Research Arm Test (ARAT) Score
Periodo de tiempo: Baseline, Day 30, and Day 90
|
Upper extremity activity performance will be assessed using the ARAT. The total score ranges from 0 to 57, with higher scores indicating better upper limb functional ability. |
Baseline, Day 30, and Day 90
|
|
National Institutes of Health Stroke Scale (NIHSS) Score
Periodo de tiempo: Baseline, Day 10, and Day 30
|
Neurological impairment will be assessed using the NIHSS. Scores range from 0 to 42, with higher scores indicating greater neurological deficit. |
Baseline, Day 10, and Day 30
|
|
Modified Rankin Scale (mRS) Score
Periodo de tiempo: Day 90
|
Global functional outcome will be assessed using the modified Rankin Scale. Scores range from 0 to 6, with higher scores indicating greater disability. |
Day 90
|
|
Modified Barthel Index (MBI) Score
Periodo de tiempo: Day 30 and Day 90
|
Activities of daily living will be assessed using the Modified Barthel Index. Higher scores indicate better functional independence. |
Day 30 and Day 90
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Training Completion Rate
Periodo de tiempo: During the 10-day intervention period
|
Feasibility outcome defined as the proportion of completed EEG-BCI or sham BCI training sessions among the planned 20 sessions. |
During the 10-day intervention period
|
|
Effective Training Duration
Periodo de tiempo: During the 10-day intervention period
|
Feasibility outcome defined as the cumulative duration of completed valid BCI training sessions during the intervention period. |
During the 10-day intervention period
|
|
EEG Signal Quality and BCI Performance Metrics
Periodo de tiempo: During the 10-day intervention period
|
Feasibility outcome assessing EEG acquisition quality and available BCI performance metrics, including signal quality and classification accuracy when available. |
During the 10-day intervention period
|
|
Follow-up completion rate
Periodo de tiempo: Through Day 90
|
Feasibility outcome defined as the proportion of randomized participants who complete scheduled outcome assessments through Day 90. |
Through Day 90
|
|
Protocol deviation rate
Periodo de tiempo: From randomization through Day 90
|
Feasibility outcome defined as the proportion of participants with one or more protocol deviations. |
From randomization through Day 90
|
|
Incidence of symptomatic intracranial hemorrhage
Periodo de tiempo: From baseline through Day 90
|
Safety outcome defined as the occurrence of symptomatic intracranial hemorrhage after randomization. |
From baseline through Day 90
|
|
Incidence of any intracranial hemorrhage
Periodo de tiempo: From baseline through Day 90
|
Safety outcome defined as the occurrence of any type of intracranial hemorrhage after randomization. |
From baseline through Day 90
|
|
Incidence of neurological deterioration
Periodo de tiempo: From baseline through Day 90
|
Safety outcome defined as clinically relevant neurological worsening after randomization, such as an increase in NIHSS score of 4 or more points without another clear explanation. |
From baseline through Day 90
|
|
Incidence of seizures
Periodo de tiempo: From baseline through Day 90
|
Safety outcome defined as the occurrence of seizure events after randomization. |
From baseline through Day 90
|
|
Incidence of Falls or Injuries
Periodo de tiempo: From baseline through Day 90
|
Safety outcome defined as the occurrence of falls during the study period. |
From baseline through Day 90
|
|
Incidence of Cardiovascular and Vital Sign Events
Periodo de tiempo: From baseline through Day 90
|
Safety outcome defined as the occurrence of clinically relevant blood pressure instability or cardiac arrhythmia events during the study period. |
From baseline through Day 90
|
|
Incidence of training-related discomfort
Periodo de tiempo: During the 10-day intervention period
|
Safety outcome defined as the occurrence of training-related discomfort, including fatigue, headache, dizziness, nausea, skin irritation, or other discomfort associated with the intervention. |
During the 10-day intervention period
|
|
Incidence of serious adverse events
Periodo de tiempo: From baseline through Day 90
|
Safety outcome defined as the occurrence of serious adverse events (SAEs), including death, life-threatening events, hospitalization or prolongation of hospitalization, persistent or significant disability, or other medically important events. |
From baseline through Day 90
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: QinJian Sun, MD, Shandong Provincial Hospital
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- SWYX.NO.2026-1053
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .